Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial. - Liu, Dan; Zhou, Jun; Wang, Yongsheng; Li, Mingjun; Jiang, Haiping; Liu, Yunpeng; Yin, Xianli; Ge, Minghua; Xiang, Xiaojun; Ying, Jieer; Huang, Jian; Zhang, Yan-qiao; et al. (BMC Medicine, 2022)